ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020
[Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)].
Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study.World journal of gastrointestinal oncology · 2024Article
- Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.Journal of clinical laboratory analysis · 2023Article
- Current Concepts of Precancerous Lesions of Hepatocellular Carcinoma: Recent Progress in Diagnosis.Diagnostics (Basel, Switzerland) · 2023Review
- High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) currently holds the second position for cause of cancer-related deaths in China. Most of the pathogenic characteristics of HCC in China follow the tri-step model of hepatitis B-cirrhosis-liver cancer. The screening of precancerous lesions of stomach cancer, colorectal cancer and cervical cancer has achieved remarkable results for the diagnosis and treatment of malignant tumors. Dysplastic nodules in the state of cirrhosis have strong potential for malignant changes, especially high-grade dysplastic nodules, have extremely high canceration rate. This expert consensus is based on the research results and clinical experience of foreign and native experts of this field. Furthermore, this consensus summarizes and defines high-grade dysplastic nodules of the liver as precancerous lesions of HCC through multidisciplinary collaboration in terms of conception, screening, diagnosis, treatment and follow-up, with the aim to reduce the HCC incidence and improve the overall therapeutic effect of HCC in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.